… seen in the response rate to gefitinib 250 or 500 mg/day (12 versus 9%). Median survival
was 7 months with gefitinib 250 mg/day and 6 months with gefitinib 500 mg/day and symptom …

Introduction: In non–small-cell lung cancer, an exon 19 deletion and an L858R point mutation
in the epidermal growth factor receptor (EGFR) are predictors of a response to EGFR-…

… patients with advanced NSCLC, gefitinib 250 and 500 mg/day … Survival Evaluation in Lung
cancer), gefitinib failed to prolong … trials of gefitinib in patients with non-small cell lung cancer. …

… In the second study, including 88 patients in Europe and Australia, gefitinib was … with either
advanced non small cell lung, ovarian, head and neck, prostate, or colorectal cancer [11]. At …

… of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor
mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403). Br J Cancer …

… Patients with lung cancer who respond to gefitinib have been reported to have somatic … to
gefitinib in initially gefitinib-sensitive patients. We describe a patient with gefitinib-resistant lung …

… leading cause of cancer death throughout the … of non–small cell lung cancers (NSCLC) and
is a major target for new therapies. In 2005, the EGFR tyrosine kinase inhibitors (TKI) gefitinib …

… Lung cancer is pathologically and clinically categorized into small cell lung cancer (SCLC)
and non-small cell lung cancer … -targeted agents such as gefitinib (IRESSA; AstraZeneca), an …

… gefitinib on progression-free survival and overall survival in patients with EGFR mutation–positive
non–small cell lung cancer… of gefitinib for advanced non–small cell lung cancer with …

… to clinical radiation resistance of non–small cell lung cancer (NSCLC). Molecular …
gefitinib, a selective EGFR tyrosine kinase inhibitor, restores the radiosensitivity of NSCLC cells…